Vyome Holdings, Inc.(HIND)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.58
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HIND

11/13/2026: HIND (1-star) is currently NOT-A-BUY. Pass it for now.

Vyome Holdings, Inc. is a clinical-stage specialty biopharmaceutical company focused on developing novel therapeutics for immuno-inflammatory and rare diseases. The company's main strengths lie in its specialized pipeline candidates, such as VT-1953 and VT-1908, and an asset-light operating model that leverages cross-border research capabilities. Its primary investment story centers on the potential clinical success and out-licensing of these novel topical programs in high-value therapeutic markets. However, the company faces significant execution risks, including micro-cap price volatility, ongoing operating losses, and heavy reliance on external capital. This stock best suits high-risk growth investors willing to monitor clinical trial milestones, regulatory updates, and cash burn metrics closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks consistent revenue scaling, though high-risk growth seekers look at its early-stage clinical pipeline.
Momentum investorStrong fit while signal remains positiveLow float and clinical catalysts can occasionally trigger sharp short-term price movements.
Value investorWeak fitOngoing operating losses and lack of earnings make traditional value metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for clinical development.
Low-risk investorWeak fitHigh clinical uncertainty, micro-cap volatility, and cash burn present substantial risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading volumes and micro-cap status result in sharp intraday and periodic price swings.
Valuation riskHighValuation is driven by speculative clinical potential rather than trailing earnings or book value.
Competition risk (biotech and pharmaceutical development)HighWell-funded competitors can out-market or out-develop smaller clinical-stage biotechs.
Business qualityMedium / highThe firm holds promising science and patents, but lacks established commercial depth.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighClinical trial success, regulatory approvals, and capital raising must be executed flawlessly to survive.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.09M USD
Price to earnings Ratio 0.89
1Y Target Price 8.83
Price to earnings Ratio 0.89
1Y Target Price 8.83
Volume (30-day avg) 11.4K shares
Beta -
52 Weeks Range 1.53 - 5.88
Updated Date 11/15/2026
52 Weeks Range 1.53 - 5.88
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.78

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -34.09%
Avg. Invested days 13
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HIND receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
HIND has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-43.9%), weak cash generation (FCF margin -1172.6%), negative revenue growth (-96.0%).

Financial Health Rating

★★★★★
HIND's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 41.6%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is HIND's strongest growth driver at +15.3% FY2025 versus FY2024 (solid, 4 stars). By comparison, while revenue growth (-96.0%, negative) and earnings growth (-43.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 2.0% and approximately 51.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 52.89% supports management-shareholder alignment.

Top 5 Institutional Investors

Citadel Advisors Llc 0.37%
Geode Capital Management, LLC 0.37%
HRT FINANCIAL LLC 0.29%
The Colony Group LLC 0.21%
Vanguard Fiduciary Trust Co 0.17%

Unit Economics (Per $1K Revenue)

★★★★★
HIND generates approximately $647 of gross profit, $-8,592 of operating income, and $-11,726 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 2.06%

Quantitative Style Profile

★★★★★
HIND has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Pharmaceutical Products & LicensingLegacy commercialized anti-fungal products and associated royalty or licensing agreements primarily in regional markets.This segment provides minor baseline revenue, but the core investment case rests on the biotechnology pipeline.
Biotechnology R&D PipelineFuture potential commercial milestones, out-licensing fees, and product sales from clinical candidates like VT-1953 and VT-1908.This segment currently generates no direct commercial product sales and operates as a capital investment center.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 0.89
Forward PE -
Enterprise Value 3.24M
Price to Sales(TTM) 72.43
Enterprise Value 3.24M
Price to Sales(TTM) 72.43
Enterprise Value to Revenue 24.94
Enterprise Value to EBITDA -
Shares Outstanding 7.02M
Shares Floating 3.65M
Shares Outstanding 7.02M
Shares Floating 3.65M
Percent Insiders 52.89
Percent Institutions 2.04

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.